Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 44,715 Shares of Stock

Key Points

• Elizabeth Reed sold 44,715 shares on April 14 at an average price of $41.21 for $1.84M, reducing her stake by 28.53% to 111,996 shares; the sale was executed under a Rule 10b5-1 plan to cover tax withholding from vested equity awards.
• FDA approval for Filspari in FSGS expanded Travere’s U.S. addressable market by roughly 30,000 patients and sparked a roughly 37% share surge, prompting multiple analyst price-target upgrades.
• Despite the approval-driven rally, the stock traded at $40.95 on high volume (~4.52M vs. avg 2.2M), has a market cap of $3.78B and a negative P/E, indicating elevated volatility even with positive commercial catalysts.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Elizabeth Reed sold 44,715 shares of the stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $41.21, for a total value of $1,842,705.15. Following the transaction, the insider owned 111,996 shares in the company, valued at $4,615,355.16. This represents a 28.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Price Performance

Shares of Travere Therapeutics stock traded down $1.18 on Wednesday, reaching $40.95. The company's stock had a trading volume of 4,521,912 shares, compared to its average volume of 2,203,580. The company has a market capitalization of $3.78 billion, a P/E ratio of -136.50 and a beta of 0.86. Travere Therapeutics, Inc. has a 52-week low of $13.88 and a 52-week high of $43.31. The stock has a 50-day moving average price of $29.57 and a 200-day moving average price of $31.37. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s rare kidney-disease franchise, adding an estimated ~30,000 patients to the U.S. addressable market and supporting multi-year revenue/earnings upside. Article Title
• Positive Sentiment: Market reacted strongly to the approval — shares jumped about ~37% on the news as investors priced in first-mover status, premium pricing potential and material volume-driven revenue growth for Filspari. Article Title
• Positive Sentiment: Multiple brokerages raised ratings/price targets following the approval (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49 overweight, Wedbush to $44, HC Wainwright reaffirmed buy). These upgrades signal increased analyst confidence in TAM expansion and revenue trajectory. Article Title
• Neutral Sentiment: Guggenheim issued a positive forecast note on TVTX that accompanies their price-target lift; this is incremental institutional support but not a guarantee of sustained momentum. Article Title
• Neutral Sentiment: Unusually high options activity and elevated trading volume were reported around the approval-related move, indicating heightened short-term speculation and positioning that can amplify volatility. Article Title
• Neutral Sentiment: Company-hosted commentary/transcripts and mainstream coverage (Seeking Alpha slides/transcript, MSN health reports) are providing more detail on label scope and commercial plans; useful for modeling uptake but not yet concrete sales figures. Article Title
• Negative Sentiment: Some analysts caution that recent earnings-estimate revision trends may limit further near-term upside despite the approval; elevated expectations and heavy short-term speculative flows raise the risk of a pullback or consolidation. Article Title

Wall Street Analyst Weigh In

Several brokerages recently commented on TVTX. Guggenheim boosted their price target on shares of Travere Therapeutics from $49.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday. Wall Street Zen downgraded shares of Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 21st. HC Wainwright reissued a "buy" rating and set a $47.00 target price on shares of Travere Therapeutics in a research note on Tuesday. Wedbush upped their price target on shares of Travere Therapeutics from $39.00 to $44.00 and gave the stock an "outperform" rating in a research report on Tuesday. Finally, Canaccord Genuity Group raised their price target on shares of Travere Therapeutics from $47.00 to $56.00 and gave the company a "buy" rating in a research note on Tuesday. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.

Institutional Trading of Travere Therapeutics

Several large investors have recently made changes to their positions in the company. Stephens Investment Management Group LLC purchased a new position in shares of Travere Therapeutics during the 3rd quarter worth $38,232,000. State Street Corp grew its stake in shares of Travere Therapeutics by 47.8% in the 4th quarter. State Street Corp now owns 4,756,666 shares of the company's stock valued at $181,752,000 after buying an additional 1,538,827 shares during the period. Wellington Management Group LLP grew its position in Travere Therapeutics by 3,331.9% in the third quarter. Wellington Management Group LLP now owns 1,201,469 shares of the company's stock worth $28,715,000 after acquiring an additional 1,166,460 shares during the period. Fiera Capital Corp acquired a new position in shares of Travere Therapeutics in the 4th quarter valued at $33,398,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Travere Therapeutics during the 2nd quarter worth $12,347,000.

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.